Produktbild: Clinical Ophthalmic Oncology

Clinical Ophthalmic Oncology Retinoblastoma

171,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

28.02.2026

Abbildungen

VI, 325 p. 110 illus., 105 illus. in color.

Herausgeber

Jesse L. Berry + weitere

Verlag

Springer

Seitenzahl

325

Maße (L/B/H)

27,9/21/1,4 cm

Gewicht

909 g

Auflage

Fourth Edition 2024

Sprache

Englisch

ISBN

978-3-031-77179-8

Beschreibung

Portrait

Jesse L. Berry, MD, received her undergraduate and medical degree from Harvard University in Massachusetts. Following her ophthalmology residency at the University of Southern California, she was the assistant chief of service at the Los Angeles County Medical Center and then completed a fellowship in Ocular Oncology at Children’s Hospital Los Angeles. Dr. Berry is the founder of WOO, Women in Ocular Oncology.

Bertil Damato, MD, PhD,  is Professor of Ophthalmology and Radiation Oncology and Director of the Ocular Oncology Service at the University of California, San Francisco. Until 2013, he was Consultant Ophthalmologist at the Royal Liverpool University Hospital, where he was Director of the Ocular Oncology Service, which he established in 1993. Dr. Damato has published more than 200 peer-reviewed articles, 68 reviews, 75 book chapters and 6 books, one as single author.

 

Arun Singh, MD , is Director of the Cole Eye Institute at Cleveland Clinic in the Department of Ophthalmic Oncology. He is also the Series Editor for Springer's  Essentials in Ophthalmology  series and was the former Editor for The British Journal of Ophthalmology and is the current Editor of Ocular Oncology and Pathology. 

 

 

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

28.02.2026

Abbildungen

VI, 325 p. 110 illus., 105 illus. in color.

Herausgeber

Verlag

Springer

Seitenzahl

325

Maße (L/B/H)

27,9/21/1,4 cm

Gewicht

909 g

Auflage

Fourth Edition 2024

Sprache

Englisch

ISBN

978-3-031-77179-8

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Clinical Ophthalmic Oncology
  • Chapter 1. Retinoblastoma: Evaluation and Diagnosis.- Chapter 2. Differential Diagnosis of Leukocoria.- Chapter 3. Retinoblastoma: Staging and Grouping.- Chapter 4. Retinoblastoma: Incidence and Etiologic Factors.- Chapter 5. Retinoblastoma: Global Burden.- Chapter 6. Retinoblastoma: Global Initiatives.- Chapter 7. Retinoblastoma Tumorigenesis.- Chapter 8. Retinoblastoma: Evolving Role of Molecular Analysis and Subtypes.- Chapter 9. Animal Models in Retinoblastoma Research.- Chapter 10. Retinocytoma or Retinoma.- Chapter 11. Retinoblastoma: Genetic Counseling and Testing.- Chapter 12. Retinoblastoma: Evolution of Treatment Methods.- Chapter 13. Retinoblastoma: Treatment Options.- Chapter 14. Retinoblastoma: Laser Treatment and Cryotherapy.- Chapter 15. Retinoblastoma: Brachytherapy.- Chapter 16. Retinoblastoma: Intravenous Chemotherapy.- Chapter 17. Retinoblastoma: Intra-ophthalmic Artery Chemotherapy.- Chapter 18. Retinoblastoma: Intravitreal / Intracameral Chemotherapy.- Chapter 19. Retinoblastoma: External beam radiation.- Chapter 20. Retinoblastoma: Enucleation.- Chapter 21. Retinoblastoma: Emerging Surgical Techniques.- Chapter 22. Retinoblastoma: Emerging Medical Techniques.- Chapter 23. Histopathologic Features and Prognostic Factors.- Chapter 24. Retinoblastoma: Aqueous Biomarkers.- Chapter 25. Retinoblastoma: Blood Biomarkers.- Chapter 26. Orbital Retinoblastoma: Diagnosis and Management.- Chapter 27. Retinoblastoma: Metastatic Disease.- Chapter 28. Retinoblastoma: Non ocular tumors and other long term complications.- Chapter 29. Trilateral Retinoblastoma.- Chapter 30. Screening Children at Risk for Retinoblastoma.- Chapter 31. Children’s Oncology Group (COG) Trials for Retinoblastoma.- Chapter 32. Social Aspects, Advocacy and Organizations.